BR112015028399A2 - derivados 11-hidroxila de ácidos biliares e conjugados de aminoácido dos mesmos como moduladores de receptor farnesoide x - Google Patents
derivados 11-hidroxila de ácidos biliares e conjugados de aminoácido dos mesmos como moduladores de receptor farnesoide xInfo
- Publication number
- BR112015028399A2 BR112015028399A2 BR112015028399A BR112015028399A BR112015028399A2 BR 112015028399 A2 BR112015028399 A2 BR 112015028399A2 BR 112015028399 A BR112015028399 A BR 112015028399A BR 112015028399 A BR112015028399 A BR 112015028399A BR 112015028399 A2 BR112015028399 A2 BR 112015028399A2
- Authority
- BR
- Brazil
- Prior art keywords
- amino acid
- farnesoid
- receptor modulators
- present
- acid derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
abstract the present invention provides a compound of formula (i): (i) or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof, wherein r1, r2, r3, r4, r5, and r6 are as described herein. the present invention relates generally to selective fxr agonists and to methods of making and using them. tradução do resumo resumo "derivados 11-hidroxila de ácidos biliares e conjugados de aminoácido dos mesmos como moduladores de receptor farnesoide x" a presente invenção refere-se a um composto de fórmula (i) ou um conjugado de aminoácido, solvato ou sal farmaceuticamente aceitável do mesmo, em que r1 é um grupo hidróxi e r2, r3, r4, r5 e r6 são conforme descritos no presente documento. a presente invenção refere-se, de modo geral, a agonistas fxr seletivos e a métodos para produzir e usar os mesmos. 26587578v1 26587578v1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361823169P | 2013-05-14 | 2013-05-14 | |
| US61/823,169 | 2013-05-14 | ||
| PCT/EP2014/059896 WO2014184271A1 (en) | 2013-05-14 | 2014-05-14 | 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112015028399A2 true BR112015028399A2 (pt) | 2017-07-25 |
| BR112015028399B1 BR112015028399B1 (pt) | 2021-11-16 |
Family
ID=50721801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015028399-3A BR112015028399B1 (pt) | 2013-05-14 | 2014-05-14 | Derivados 11-hidroxila de ácidos biliares e conjugados de aminoácido dos mesmos como moduladores de receptor farnesoide x, composição farmacêutica e uso dos referidos derivados |
Country Status (38)
| Country | Link |
|---|---|
| US (7) | US9611289B2 (pt) |
| EP (4) | EP3360882B1 (pt) |
| JP (2) | JP6326131B2 (pt) |
| KR (1) | KR102229952B1 (pt) |
| CN (2) | CN108245523B (pt) |
| AU (1) | AU2014267324B2 (pt) |
| BR (1) | BR112015028399B1 (pt) |
| CA (1) | CA2912139C (pt) |
| CL (2) | CL2015003344A1 (pt) |
| CR (1) | CR20150643A (pt) |
| CY (1) | CY1122614T1 (pt) |
| DK (4) | DK3360882T3 (pt) |
| EA (1) | EA030152B1 (pt) |
| ES (4) | ES2936638T3 (pt) |
| GT (1) | GT201500324A (pt) |
| HK (2) | HK1221471A1 (pt) |
| HR (1) | HRP20180931T1 (pt) |
| HU (1) | HUE037996T2 (pt) |
| IL (2) | IL242555B (pt) |
| LT (1) | LT2997035T (pt) |
| MA (1) | MA38647B1 (pt) |
| ME (1) | ME03082B (pt) |
| MX (1) | MX352065B (pt) |
| MY (1) | MY187886A (pt) |
| NI (1) | NI201500160A (pt) |
| PE (1) | PE20160665A1 (pt) |
| PH (1) | PH12015502576B1 (pt) |
| PL (3) | PL2997035T3 (pt) |
| PT (3) | PT2997035T (pt) |
| RS (1) | RS57372B1 (pt) |
| SA (1) | SA515370140B1 (pt) |
| SG (1) | SG11201509352XA (pt) |
| SI (3) | SI2997035T1 (pt) |
| SM (1) | SMT201800326T1 (pt) |
| TN (1) | TN2015000497A1 (pt) |
| TR (1) | TR201809041T4 (pt) |
| UA (1) | UA118673C2 (pt) |
| WO (1) | WO2014184271A1 (pt) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002072598A1 (en) | 2001-03-12 | 2002-09-19 | Roberto Pellicciari | Steroids as agonists for fxr |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| WO2014184271A1 (en) | 2013-05-14 | 2014-11-20 | Tes Pharma Srl. | 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators |
| US10077268B2 (en) | 2014-03-13 | 2018-09-18 | Salk Institute For Biological Studies | FXR agonists and methods for making and using |
| US10301268B2 (en) | 2014-03-13 | 2019-05-28 | The Salk Institute For Biological Studies | Analogs of fexaramine and methods of making and using |
| PL3626725T3 (pl) | 2014-05-29 | 2023-04-03 | Bar Pharmaceuticals S.R.L. | Pochodne cholanu do zastosowania w leczeniu i/lub zapobieganiu chorobom, w których pośredniczy fxr i tgr5/gpbar1 |
| JP2017533923A (ja) | 2014-11-06 | 2017-11-16 | エナンタ ファーマシューティカルズ インコーポレイテッド | Ｆｘｒ／ｔｇｒ５アゴニストとしての胆汁酸類似体およびその使用方法 |
| MX2017006564A (es) | 2014-11-19 | 2018-01-26 | Nzp Uk Ltd | Esteroides 5.beta.-6-alquil-7-hidroxi-3-ona como intermedios para la produccion de moduladores esteroideos del receptor x farnesoide (fxr). |
| EP3221334B1 (en) | 2014-11-19 | 2020-02-19 | Nzp Uk Limited | 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators |
| JP6735748B2 (ja) | 2014-11-19 | 2020-08-05 | エヌゼットピー ユーケー リミテッド | ステロイドＦＸＲモジュレーター製造のための中間体としての６α−アルキル−３，７−ジオン−ステロイド |
| WO2016079517A1 (en) | 2014-11-19 | 2016-05-26 | Dextra Laboratories Limited | 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| WO2016086115A1 (en) | 2014-11-26 | 2016-06-02 | Enanta Pharmaceuticals, Inc. | Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof |
| EP3223823A4 (en) | 2014-11-26 | 2018-10-17 | Enanta Pharmaceuticals, Inc. | Bile acid analogs as fxr/tgr5 agonists and methods of use thereof |
| MA41094A (fr) * | 2014-12-02 | 2017-10-10 | Lilly Co Eli | Procédés de traitement de troubles rénaux |
| CN105348365A (zh) * | 2014-12-03 | 2016-02-24 | 四川百利药业有限责任公司 | 一种胆酸衍生物及其制备方法、药物组合物和用途 |
| CN104523703A (zh) * | 2014-12-24 | 2015-04-22 | 聂飚 | 一种游离脂肪酸转运蛋白小分子抑制物的应用 |
| CA2976056C (en) * | 2015-02-06 | 2024-02-06 | Intercept Pharmaceuticals, Inc. | Pharmaceutical compositions for combination therapy |
| US10246483B2 (en) | 2015-02-11 | 2019-04-02 | Enanta Pharmaceuticals, Inc. | Bile acid analogs as FXR/TGR5 agonists and methods of use thereof |
| US20180042943A1 (en) * | 2015-03-09 | 2018-02-15 | Intercept Pharmaceuticals, Inc. | Methods for modulating bone density |
| CN107531741A (zh) | 2015-03-10 | 2018-01-02 | 美莱斯股份有限公司 | 氟化和烷基化胆酸 |
| KR20170123658A (ko) * | 2015-03-13 | 2017-11-08 | 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 장 수용체를 활성화시키는 파네소이드 x 수용체 작용제를 사용한 성인 잠복성 자가면역 당뇨병의 치료 |
| EP3277286B1 (en) | 2015-03-31 | 2021-04-21 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| AU2016246524B2 (en) | 2015-04-07 | 2021-04-01 | Intercept Pharmaceuticals, Inc. | Pharmaceutical compositions for combination therapy |
| WO2016168553A1 (en) * | 2015-04-17 | 2016-10-20 | Concert Pharmaceuticals, Inc. | Deuterated obeticholic acid |
| PE20180690A1 (es) | 2015-04-27 | 2018-04-23 | Intercept Pharmaceuticals Inc | Composiciones de acido obeticolico y metodos de uso |
| CN106478759A (zh) * | 2015-08-31 | 2017-03-08 | 陕西合成药业股份有限公司 | 奥贝胆酸衍生物及其制备方法和用途 |
| AU2016326428A1 (en) * | 2015-09-21 | 2018-04-12 | Intercept Pharmaceuticals, Inc. | Methods of promoting hepatic regeneration |
| ES2898705T3 (es) * | 2015-10-07 | 2022-03-08 | Intercept Pharmaceuticals Inc | Moduladores de los receptores farnesoides x |
| US10323060B2 (en) | 2016-02-23 | 2019-06-18 | Enanta Pharmaceuticals, Inc. | Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof |
| WO2017147159A1 (en) | 2016-02-23 | 2017-08-31 | Enanta Pharmaceuticals, Inc. | Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| US10323061B2 (en) | 2016-02-23 | 2019-06-18 | Enanta Pharmaceuticals, Inc. | Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof |
| KR102359191B1 (ko) * | 2016-03-11 | 2022-02-04 | 인터셉트 파마슈티컬즈, 인크. | 3-데속시 유도체 및 이의 약제학적 조성물 |
| WO2017180577A1 (en) * | 2016-04-13 | 2017-10-19 | Intercept Pharmaceuticals, Inc. | Methods of treating cancer |
| GB201608777D0 (en) | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Compounds |
| CA2968836A1 (en) | 2016-06-13 | 2017-12-13 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
| EP3730487B1 (en) | 2016-06-13 | 2022-04-27 | Gilead Sciences, Inc. | Azetidine derivatives as fxr (nr1h4) modulators |
| WO2018102418A1 (en) | 2016-11-29 | 2018-06-07 | Enanta Pharmaceuticals, Inc. | Process for preparation of sulfonylurea bile acid derivatives |
| US10472386B2 (en) | 2017-02-14 | 2019-11-12 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR agonists and methods of use thereof |
| CN110300580A (zh) | 2017-02-21 | 2019-10-01 | 基恩菲特公司 | Ppar激动剂与fxr激动剂的组合 |
| BR112019017417A2 (pt) * | 2017-02-23 | 2020-04-07 | Intercept Pharmaceuticals Inc | composições farmacêuticas de um derivado de um ácido biliar e microbioma e usos das mesmas |
| CN110461328A (zh) | 2017-03-28 | 2019-11-15 | 吉利德科学公司 | 治疗肝疾病的治疗组合 |
| AU2018249950B2 (en) | 2017-04-07 | 2023-09-21 | Enanta Pharmaceuticals, Inc. | Process for preparation of sulfonyl carbamate bile acid derivatives |
| WO2018226724A1 (en) * | 2017-06-05 | 2018-12-13 | Intercept Pharmaceuticals, Inc. | Treatment and prevention of diabetic eye diseases with a bile acid derivatives |
| AU2018288883B2 (en) * | 2017-06-23 | 2022-06-02 | Intercept Pharmaceuticals, Inc. | Methods and intermediates for the preparation of bile acid derivatives |
| MA49704A (fr) | 2017-07-24 | 2021-03-31 | Intercept Pharmaceuticals Inc | Dérivés d'acide biliaire à marquage isotopique |
| GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
| CN109182451B (zh) * | 2018-08-21 | 2021-06-11 | 四川大学 | 细胞色素cyp3a7酶的新型特异性探针反应及其应用 |
| BR112021011762A2 (pt) | 2019-01-15 | 2021-11-03 | Gilead Sciences Inc | Compostos para modulação de fxr (nr1h4) |
| CA3129949C (en) | 2019-02-19 | 2024-04-30 | Gilead Sciences, Inc. | Solid forms of fxr agonists |
| BR112021024109A2 (pt) | 2019-05-30 | 2022-03-22 | Intercept Pharmaceuticals Inc | Composições farmacêuticas compreendendo um agonista fxr e um fibrato para uso no tratamento de doença hepática colestática |
| MX2022000742A (es) | 2019-07-18 | 2022-02-14 | Enyo Pharma | Metodo para disminuir los efectos adversos del interferon. |
| CN110540955B (zh) * | 2019-08-28 | 2021-09-17 | 北京协同创新研究院 | 一种提高分化细胞中nrob2基因表达量的方法 |
| IL293892A (en) | 2020-01-15 | 2022-08-01 | Inserm Institut National De La Sant? Et De La Rech M?Dicale | Use of fxr agonists to treat hepatitis d virus infection |
| WO2022152770A1 (en) | 2021-01-14 | 2022-07-21 | Enyo Pharma | Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection |
| TW202308629A (zh) | 2021-04-28 | 2023-03-01 | 法商Ｅｎｙｏ製藥公司 | 使用fxr激動劑作為組合治療以增強tlr3激動劑之療效 |
| WO2022233398A1 (en) * | 2021-05-04 | 2022-11-10 | Kostner Pharma Gmbh | COMPOUNDS FOR REDUCING LIPOPROTEIN(a) |
| WO2023288123A1 (en) | 2021-07-16 | 2023-01-19 | Interecept Pharmaceuticals, Inc. | Methods and intermediates for the preparation of 3.alpha.,7.alpha.,11.beta.-trihydroxy-6.alpha.-ethyl-5.beta.-cholan-24-oic acid |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2080775A (en) * | 1934-08-22 | 1937-05-18 | Celanese Corp | Shedding mechanism for circular looms |
| US2802775A (en) * | 1953-05-29 | 1957-08-13 | Merck & Co Inc | 11 alpha-hydroxylation of steroids by aspergillus ochraceus |
| JPS59205396A (ja) * | 1983-05-09 | 1984-11-20 | Kuraray Co Ltd | １１β−ヒドロキシプレグナ−４−エン−３−オン−２０−カルブアルデヒド及びその製造法 |
| AU2389100A (en) | 1998-12-23 | 2000-07-12 | Glaxo Group Limited | Assays for ligands for nuclear receptors |
| ITMI20021532A1 (it) * | 2002-07-12 | 2004-01-12 | Roberto Pellicciari | Composti chimici |
| EP1568706A1 (en) * | 2004-02-26 | 2005-08-31 | Intercept Pharmaceuticals, Inc. | Novel steroid agonist for FXR |
| ES2533993T3 (es) * | 2004-03-12 | 2015-04-16 | Intercept Pharmaceuticals, Inc. | Tratamiento de fibrosis usando ligandos de FXR |
| EP2040713B1 (en) * | 2006-06-27 | 2014-06-18 | Intercept Pharmaceuticals Inc. | Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions |
| WO2014184271A1 (en) | 2013-05-14 | 2014-11-20 | Tes Pharma Srl. | 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators |
-
2014
- 2014-05-14 WO PCT/EP2014/059896 patent/WO2014184271A1/en active Application Filing
- 2014-05-14 PT PT147238208T patent/PT2997035T/pt unknown
- 2014-05-14 ME MEP-2018-159A patent/ME03082B/me unknown
- 2014-05-14 HU HUE14723820A patent/HUE037996T2/hu unknown
- 2014-05-14 AU AU2014267324A patent/AU2014267324B2/en active Active
- 2014-05-14 PL PL14723820T patent/PL2997035T3/pl unknown
- 2014-05-14 DK DK18163623.4T patent/DK3360882T3/da active
- 2014-05-14 RS RS20180690A patent/RS57372B1/sr unknown
- 2014-05-14 DK DK18163622.6T patent/DK3360881T3/da active
- 2014-05-14 MY MYPI2015002734A patent/MY187886A/en unknown
- 2014-05-14 EP EP18163623.4A patent/EP3360882B1/en active Active
- 2014-05-14 ES ES20211780T patent/ES2936638T3/es active Active
- 2014-05-14 SG SG11201509352XA patent/SG11201509352XA/en unknown
- 2014-05-14 CN CN201810162562.4A patent/CN108245523B/zh not_active Expired - Fee Related
- 2014-05-14 CN CN201480036949.5A patent/CN105377870B/zh active Active
- 2014-05-14 JP JP2016513357A patent/JP6326131B2/ja active Active
- 2014-05-14 BR BR112015028399-3A patent/BR112015028399B1/pt active IP Right Grant
- 2014-05-14 EP EP14723820.8A patent/EP2997035B8/en active Active
- 2014-05-14 KR KR1020157034951A patent/KR102229952B1/ko active IP Right Grant
- 2014-05-14 PE PE2015002397A patent/PE20160665A1/es unknown
- 2014-05-14 EP EP18163622.6A patent/EP3360881B1/en active Active
- 2014-05-14 EP EP20211780.0A patent/EP3848038B1/en active Active
- 2014-05-14 US US14/120,366 patent/US9611289B2/en active Active
- 2014-05-14 LT LTEP14723820.8T patent/LT2997035T/lt unknown
- 2014-05-14 TN TN2015000497A patent/TN2015000497A1/en unknown
- 2014-05-14 UA UAA201511098A patent/UA118673C2/uk unknown
- 2014-05-14 ES ES18163622T patent/ES2847002T3/es active Active
- 2014-05-14 SI SI201430701T patent/SI2997035T1/sl unknown
- 2014-05-14 DK DK20211780.0T patent/DK3848038T3/da active
- 2014-05-14 PT PT181636226T patent/PT3360881T/pt unknown
- 2014-05-14 PL PL18163622T patent/PL3360881T3/pl unknown
- 2014-05-14 ES ES14723820.8T patent/ES2671427T3/es active Active
- 2014-05-14 SI SI201431742T patent/SI3360881T1/sl unknown
- 2014-05-14 EA EA201592055A patent/EA030152B1/ru unknown
- 2014-05-14 ES ES18163623T patent/ES2843737T3/es active Active
- 2014-05-14 MX MX2015015730A patent/MX352065B/es active IP Right Grant
- 2014-05-14 TR TR2018/09041T patent/TR201809041T4/tr unknown
- 2014-05-14 SI SI201431741T patent/SI3360882T1/sl unknown
- 2014-05-14 PL PL18163623T patent/PL3360882T3/pl unknown
- 2014-05-14 CA CA2912139A patent/CA2912139C/en active Active
- 2014-05-14 SM SM20180326T patent/SMT201800326T1/it unknown
- 2014-05-14 DK DK14723820.8T patent/DK2997035T3/en active
- 2014-05-14 PT PT181636234T patent/PT3360882T/pt unknown
- 2014-05-14 MA MA38647A patent/MA38647B1/fr unknown
-
2015
- 2015-11-12 IL IL242555A patent/IL242555B/en active IP Right Grant
- 2015-11-12 SA SA515370140A patent/SA515370140B1/ar unknown
- 2015-11-13 PH PH12015502576A patent/PH12015502576B1/en unknown
- 2015-11-13 CL CL2015003344A patent/CL2015003344A1/es unknown
- 2015-11-13 GT GT201500324A patent/GT201500324A/es unknown
- 2015-11-13 NI NI201500160A patent/NI201500160A/es unknown
- 2015-12-07 CR CR20150643A patent/CR20150643A/es unknown
-
2016
- 2016-07-15 CL CL2016001809A patent/CL2016001809A1/es unknown
- 2016-08-15 HK HK16109719.3A patent/HK1221471A1/zh unknown
- 2016-08-15 HK HK18112619.6A patent/HK1253326A1/zh unknown
-
2017
- 2017-02-16 US US15/434,685 patent/US20170216316A1/en not_active Abandoned
-
2018
- 2018-04-13 JP JP2018077654A patent/JP2018127481A/ja not_active Withdrawn
- 2018-06-01 CY CY20181100583T patent/CY1122614T1/el unknown
- 2018-06-15 HR HRP20180931TT patent/HRP20180931T1/hr unknown
- 2018-09-06 US US16/124,139 patent/US10532061B2/en active Active
-
2019
- 2019-11-26 US US16/695,528 patent/US11000532B2/en active Active
-
2020
- 2020-02-17 IL IL272718A patent/IL272718B/en active IP Right Grant
-
2021
- 2021-04-13 US US17/228,819 patent/US20210228599A1/en not_active Abandoned
-
2023
- 2023-04-03 US US18/295,091 patent/US20230233581A1/en not_active Abandoned
-
2024
- 2024-08-12 US US18/800,808 patent/US20240398834A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015028399A2 (pt) | derivados 11-hidroxila de ácidos biliares e conjugados de aminoácido dos mesmos como moduladores de receptor farnesoide x | |
| BR112018006892A2 (pt) | moduladores do receptor farnesoide x | |
| BR112015009395A2 (pt) | processo para preparação de derivados do ácido biliar | |
| BR112017010893A2 (pt) | análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos | |
| BR112016009630A8 (pt) | receptores de farnesoide x, seus usos, composição farmacêutica, e combinação | |
| BR112015031903A2 (pt) | composto, sal farmaceuticamente aceitável do composto, composição farmacêutica e utilização de um composto | |
| BR112014013661A2 (pt) | Derivados de nucleosídeos 2,4-difluoro-2-metil substituídos como inibidores de replicação de hcv-rna | |
| BR122018070508B8 (pt) | derivados de arilamida triazol-substituída e seu uso | |
| EA201501122A8 (ru) | Новые агонисты соматостатиновых рецепторов подтипа 4 (sstr4) | |
| CY1120378T1 (el) | Υποκατεστημενα παραγωγα του διφαινυλο βουτανοϊκου φωσφονικου οξεος ως αναστολεις νερ (ουδετερης ενδοπεπτιδασης) | |
| BR112014011850A2 (pt) | derivados de aminopirimidina como moduladores de lrrk2 | |
| BR112015019590A2 (pt) | derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv | |
| BRPI0606644A2 (pt) | derivados de 4-carboxamida tiazola | |
| BR112012013854A2 (pt) | derivados de oxazina. | |
| BR112015004529A8 (pt) | alcóxi pirazóis, seu uso como ativadores de guanilato ciclase solúvel e composição farmacêutica que os compreende | |
| BR112014014452A2 (pt) | derivados de pirazolpiridina, processo de preparação dos mesmos e uso terapêutico dos mesmos | |
| BR112018069712A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a. | |
| BR112013030391A2 (pt) | derivados de piperidina 3- espirocíclicos como agonistas dos receptores de grelina | |
| BR112018071441A2 (pt) | métodos para a preparação de ácido obeticólico e derivados do mesmo | |
| BR112018015191A2 (pt) | compostos de 6,7-di-hidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida | |
| BR112013027395A2 (pt) | inibidores de 17alfa-hidroxilase/c17,20-liase | |
| ECSP14013158A (es) | Moduladores alostéricos positivos del receptor de acetilcolina nicotínico | |
| BR112015005560A2 (pt) | derivados de macrolídeos, sua preparação e seu uso terapêutico | |
| BR112015024060A2 (pt) | composto, composição farmacêutica, método para o tratamento de doenças e uso de um composto | |
| BRPI0911622B8 (pt) | derivados de benzoxepina e benzociclo-heptano, seu processo de preparação, seu uso e composição farmacêutica que os compreende |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B25G | Requested change of headquarter approved |
Owner name: INTERCEPT PHARMACEUTICALS, INC. (US) |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/05/2014, OBSERVADAS AS CONDICOES LEGAIS. |